利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.034 秒)

    CLK-PEPTIDE AND SLK-PEPTIDE
    11.
    发明申请
    CLK-PEPTIDE AND SLK-PEPTIDE 有权
    CLK-PEPTIDE和SLK-PEPTIDE

    公开(公告)号：US20100226852A1

    公开(公告)日：2010-09-09

    申请号：US12643926

    申请日：2009-12-21

    申请人： Peter C. Brooks ,  Jennifer Roth ,  Abebe Akalu

    发明人： Peter C. Brooks ,  Jennifer Roth ,  Abebe Akalu

    IPC分类号： A61K51/00 ,  A61K49/00 ,  G01N33/53

    CPC分类号： A61K38/08 ,  A61K38/10

    摘要： The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo. The invention further describes methods for treating tumors using said antagonists in combination with radiation therapy and therapies comprising the antagonists and radiation treatment.

    摘要翻译： 本发明描述了通过施用特异性结合蛋白水解或变性的IV型胶原蛋白的拮抗剂来抑制组织中的血管发生的方法，其具有比IV型胶原天然三螺旋形式更大的亲和力。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。 本发明还描述了使用所述拮抗剂结合放射疗法治疗肿瘤的方法和包括拮抗剂和放射治疗的疗法。

    CLK-peptide and SLK-peptide
    12.
    发明授权
    CLK-peptide and SLK-peptide 失效
    CLK-肽和SLK-肽

    公开(公告)号：US07601694B2

    公开(公告)日：2009-10-13

    申请号：US10782728

    申请日：2004-02-18

    申请人： Peter C. Brooks ,  Jennifer M. Roth

    发明人： Peter C. Brooks ,  Jennifer M. Roth

    IPC分类号： A61K38/10

    CPC分类号： A61K38/10 ,  A61K38/08

    摘要： The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured collagen type-IV with substantially greater affinity than to the native triple helical form of collagen type-IV. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.

    摘要翻译： 本发明描述了通过施用特异性结合蛋白水解或变性的IV型胶原蛋白的拮抗剂来抑制组织中的血管发生的方法，其具有比IV型胶原天然三螺旋形式更大的亲和力。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。

    STQ peptides
    13.
    发明授权
    STQ peptides 有权
    STQ肽

    公开(公告)号：US07387998B2

    公开(公告)日：2008-06-17

    申请号：US10797626

    申请日：2004-03-09

    申请人： Peter C. Brooks ,  Abebe Akalu

    发明人： Peter C. Brooks ,  Abebe Akalu

    IPC分类号： A61K38/00 ,  A61K38/04

    CPC分类号： C07K7/08

    摘要： The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.

    摘要翻译： 本发明描述了通过施用与蛋白水解或变性层粘连蛋白特异性结合的拮抗剂，以比天然形式的层粘连蛋白具有更大的亲和力来抑制组织中血管生成的方法。 还描述了利用这种拮抗剂治疗肿瘤生长，肿瘤转移或再狭窄的方法，以及在体内和体外在正常或患病组织中使用这些拮抗剂作为血管生成诊断标志物的方法。

    Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
    14.
    发明授权
    Methods and compositions useful for inhibition of αvβ5mediated angiogenesis 有权
    用于抑制alphavbeta5介导的血管发生的方法和组合物

    公开(公告)号：US07053041B1

    公开(公告)日：2006-05-30

    申请号：US09194552

    申请日：1997-05-30

    申请人： Peter C. Brooks ,  David A. Cheresh ,  Martin Friedlander

    发明人： Peter C. Brooks ,  David A. Cheresh ,  Martin Friedlander

    IPC分类号： A01N61/00 ,  A01N37/18 ,  A61K31/00 ,  A61K38/00

    CPC分类号： A61K38/57 ,  A61K2039/505 ,  C07K16/2839 ,  C07K16/2848 ,  C07K2317/76

    摘要： The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin αvβ5 antagonists. The αvβ5-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor. Inhibition of αvβ5-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing αvβ5 antagonists.

    摘要翻译： 本发明描述了使用玻连蛋白α5β5拮抗剂抑制组织中血管生成的方法。 α-β5介导的血管发生与包括血管内皮生长因子，转化生长因子-α和表皮生长因子在内的细胞因子的暴露相关。 使用含有αV的治疗组合物，在血管内皮细胞新生血管疾病，肿瘤生长和炎性病症中，对α5β5介导的血管生成的抑制是特别优选的 5β拮抗剂。

    Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
    16.
    发明授权
    Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins 失效
    使用基于MMP-9和β1整联蛋白的拮抗剂抑制血管生成的方法和组合物

    公开(公告)号：US07566449B2

    公开(公告)日：2009-07-28

    申请号：US11089999

    申请日：2005-03-25

    申请人： Peter C. Brooks ,  Dorothy Rodriguez

    发明人： Peter C. Brooks ,  Dorothy Rodriguez

    IPC分类号： A61K39/395

    CPC分类号： C07K16/2842 ,  C07K2317/34

    摘要： Antagonists for modifying protein-protein interactions involving certain amino acid sequences within MMP-9 and/or β1 integrins are described. Such antagonists inhibit angiogenesis, tumor growth and disease states. Example antagonists are polypeptide and non-polypeptide molecules, including the novel antibody Mab FM155 and the novel synthetic peptide FRIP-1. Methods for inhibiting angiogenesis and disease states by administering such antagonists are disclosed. Methods for identifying antagonists that modify protein-protein interactions involving certain amino acid sequences within MMP-9 and/or β1 integrins are also described.

    摘要翻译： 描述了用于修饰涉及MMP-9和/或β1整联蛋白中某些氨基酸序列的蛋白质 - 蛋白质相互作用的拮抗剂。 这种拮抗剂抑制血管发生，肿瘤生长和疾病状态。 示例性拮抗剂是多肽和非多肽分子，包括新型抗体Mab FM155和新型合成肽FRIP-1。 公开了通过施用这种拮抗剂来抑制血管生成和疾病状态的方法。 还描述了用于鉴定修饰涉及MMP-9和/或β1整联蛋白中某些氨基酸序列的蛋白质 - 蛋白质相互作用的拮抗剂的方法。

    Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
    20.
    发明授权
    Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2 失效
    使用基于MMP-2内的序列的化合物抑制血管生成和肿瘤生长的方法和组合物

    公开(公告)号：US07019108B2

    公开(公告)日：2006-03-28

    申请号：US09872165

    申请日：2001-06-01

    申请人： Peter C. Brooks ,  Dorothy Rodriguez

    发明人： Peter C. Brooks ,  Dorothy Rodriguez

    IPC分类号： A61K38/00

    CPC分类号： C12N9/6491 ,  A61K38/00 ,  C12Q1/37

    摘要： The present invention provides methods and compositions for inhibiting angiogenesis, tumor growth and treating disease states using a peptide that contains a specific amino acid sequence of matrix metalloproteinase 2 (MMP-2). In one embodiment, the invention provides a peptide, which comprises the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini. Additionally, the invention provides compositions for inhibiting angiogenesis or tumor growth or for treating disease states comprising organic and non-peptidic mimetics based on the above amino acid sequence as well as optimized sequences flanking the region of MMP-2 within which the sequence lies. Also provided are methods for detecting angiogenesis, tumorous tissue, metastases, and tumor invasion into a tissue by contacting a composition of the invention with a tissue and methods for screening compositions of the invention.

    摘要翻译： 本发明提供了使用含有基质金属蛋白酶2（MMP-2）的特定氨基酸序列的肽来抑制血管发生，肿瘤生长和治疗疾病状态的方法和组合物。 在一个实施方案中，本发明提供了一种肽，其包含氨基酸序列Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg，优选在氨基和羧基末端侧接半胱氨酸残基。 另外，本发明提供了用于抑制血管发生或肿瘤生长或用于治疗疾病状态的组合物，其包含基于上述氨基酸序列的有机和非肽模拟物以及序列所在的MMP-2区域侧翼的优化序列。 还提供了通过将本发明的组合物与组织接触并筛选本发明组合物的方法来检测血管生成，肿瘤组织，转移和肿瘤侵入组织的方法。